Buy Verastem Stock VSTM Stock Price Today & News

Zacks Earnings ESP looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. With the third month of 2023 already well underway, the ripple effect from the collapse of multiple banks in the United States is felt far and wide, leaving investors to wonder which stocks are worthy… Robinhood gives you the tools you need to put your money in motion. You can buy or sell Verastem and other ETFs, options, and stocks.

High institutional ownership can be a signal of strong market trust in this company. MarketBeat has tracked 8 news articles for Verastem this week, compared to 1 article on an average week. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

Verastem (VSTM) Upgraded to Strong Buy: What Does It Mean for the Stock?

This puts Robert Forrester in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Verastem’s stock was trading at $0.4025 on January 1st, 2023. Since then, VSTM stock has increased by 6.8% and is now trading at $0.43. 0.55% of the outstanding shares of Verastem have been sold short. Verastem Inc is a biopharmaceutical how to identify base and counter currencies company focused on discovering and developing proprietary small molecule drugs targeting cancer stem cells along with proprietary companion diagnostics. If Verastem takes out the full calculated possible swing range there will be an estimated 22.56% move between the lowest and the highest trading price during the day.

The Company’s pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition. Its advanced product candidates, VS-6766 and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including, low-grade serous ovarian cancer … FDA gave breakthrough designation..Verastem announced it received FDA Breakthrough Therapy designation for VS-6766 with defactinib in recurrent low-grade serous ovarian cancer. If the flag holds, it looks like it could hit around $4.60.

Verastem reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.099. Following the earnings report the stock price went same N/A. Verastem released its earnings results on Mar 14, 2023. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.099 by $0.019. Verastem reports interim data from Part A of the ongoing RAMP 201 Phase 2 study Verastem Oncology announces positive interim data from Part A of the ongoing RAMP 201 international registration-directed Phase 2… Verastem reports Q4 EPS , consensus Verastem Oncology ended the fourth quarter of 2022 with cash, cash equivalents and investments of $87.9M.

VSTM Overview

Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.

Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. A handful of earnings surprises are likely to keep investors busy early Thursday. 12.65% during the next 3 months and, with a 90% probability hold a price between $0.445 and $0.84 at the end of this 3-month period. The industry with the best average Zacks Rank would be considered the top industry , which would place it in the top 1% of Zacks Ranked Industries.

Verastem Inc

For more information on risks and conflicts of interest, see these disclosures. Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase and the phosphoinositide 3-kinase /mTOR signaling pathways. Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market.

The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure. Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.

Verastem started at buy with $14 stock price target at Seaport Global

If this is broken, then the next support from accumulated volume will be at $0.386 and $0.330. The technique has proven to be very useful for finding positive surprises. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. These three low-priced cancer stocks could be grossly undervalued. George Budwell Biotech stocks have been some of the most reliable capital-appreciation vehicles in the entire market for the past two decades. Sign up for a Robinhood brokerage account to buy or sell Verastem stock and options commission-free.

Only 3.20% of the stock of Verastem is held by insiders. Only 8 people have added Verastem to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. 20 people have searched for VSTM on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

This suggests a possible upside of 888.4% from the stock’s current price. View analysts price targets for VSTM or view top-rated stocks among Wall Street analysts. 5 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Verastem in the last twelve months. The consensus among Wall Street equities research analysts is that investors should “buy” VSTM shares. Verastem Oncology is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer.

• Verastem exhibits a price/book ratio which is within a 15% range of the industry average for drugs stocks listed on the NASDAQ.
• Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations.
• The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.
• Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

Therefore, we hold a negative evaluation of this stock. On the downside, the stock finds support just below today’s level from accumulated volume at $0.391 and $0.386. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Verastem finds support just below today’s level at $0.391.

JSI uses funds from your Treasury Account to purchase T-bills in increments of $100 “par value” (the T-bill’s value at maturity). The value of T-bills fluctuate and investors may receive more or less https://day-trading.info/ than their original investments if sold prior to maturity. T-bills are subject to price change and availability – yield is subject to change. Past performance is not indicative of future performance.

This is not an offer, solicitation of an offer, or advice to buy or sell securities or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured. Apex Clearing Corporation, our clearing firm, has additional insurance coverage in excess of the regular SIPC limits. Discuss news and analysts’ price predictions with the investor community. Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world’s media organizations, industry events and directly to consumers.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. In the past three months, Verastem insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $443.00 in company stock. Verastem has only been the subject of 2 research reports in the past 90 days. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Verastem has been upgraded to a Zacks Rank #1 , reflecting growing optimism about the company’s earnings prospects.

Some negative signals were issued as well, and these may have some influence on the near short-term development. The Verastem stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.

Verastem announced it received FDA Breakthrough Therapy designation for VS-6766 with defactinib in recurrent low-grade serous ovarian cancer. Verastem’s market cap is calculated by multiplying VSTM’s current stock price of $0.43 by VSTM’s total outstanding shares of 200,677,979. Brokerage services for alternative assets available on Public are offered by Dalmore Group, LLC (“Dalmore”), member of FINRA & SIPC. “Alternative assets,” as the term is used at Public, are equity securities that have been issued pursuant to Regulation A of the Securities Act of (“Regulation A”).